Skip to content
Dosage GuideResearch Reference

PACAP Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for PACAP. All information is for educational purposes only.

Quick Answer

Due to its short half-life and limited human trials, PACAP dosage is largely experimental. Animal studies typically use doses ranging from 1-100 mcg/kg via intravenous or subcutaneous injection. Translation to human dosage is complex, and current research typically uses low microgram doses. Consultation with a qualified healthcare practitioner is crucial.

→ PACAP Benefits→ PACAP Side Effects→ Full PACAP Profile
Table of Contents

Standard Dosage Range

Research dosing range: Experimental; 10–100 mcg (subcutaneous/intranasal suggested)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Neuroprotection (Post-Stroke/TBI)

10–50 mcg1–2× daily
Duration

2–4 weeks

Subcutaneous or intranasal administration. Animal studies suggest benefit within hours of injury. Dosing frequency and duration extrapolated from preclinical models.

Migraine Prophylaxis

20–100 mcg1× daily
Duration

4–8 weeks

Intranasal administration may be preferred for faster onset. PACAP is implicated in migraine pathophysiology; dosing is highly experimental.

Cognitive Enhancement/Memory Support

10–30 mcg1× daily
Duration

4–12 weeks

Subcutaneous or intranasal. Research is preliminary. Consider cycling to mitigate potential tolerance.

PTSD Biomarker Research

N/AN/A
Duration

N/A

PACAP levels are being explored as a potential biomarker for PTSD, particularly in women. Dosage information is not applicable in this context.

Timing & Frequency

Given the short half-life, multiple daily doses may be required for sustained effects. Subcutaneous injections are typically administered in the morning. Intranasal administration allows for rapid absorption.

Cycle Guidance

Cycling is advised due to limited long-term human safety data and the potential for receptor desensitization. A common research protocol uses a 4–8 week cycle followed by a 2–4 week break.

Reconstitution Reference

Quick reference for reconstituting PACAP. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 1 mg per vial
BAC Water Volume1 mL bacteriostatic water for 1 mg/mL concentration
Concentration & DrawAt 1 mg/mL: 10 mcg = 0.01 mL (1 unit on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at -20°C for long-term storage.
StabilityReconstituted solution stable up to 7 days refrigerated. Lyophilized powder stable 12–24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the best way to administer PACAP?
Subcutaneous injection and intranasal administration are the most practical methods. Intravenous administration is also possible but requires medical supervision. Oral bioavailability is likely very low due to rapid degradation.
What are the potential side effects of PACAP?
Due to limited human data, potential side effects are not well-defined. Hypotension, flushing, and headaches are theoretical possibilities based on PACAP's known mechanisms. Start with a low dose and monitor for adverse reactions.

Last updated: 2026-02-19